Cerenome vs Lucid Diagnostics
CNSY and LUCD side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CNSY and LUCD compare
Lucid Diagnostics is the larger company, worth 13 times as much as Cerenome ($91.3M against $7.2M).
Lucid Diagnostics grew revenue faster over the last twelve months (23.6% versus −32.9% for Cerenome).
Cerenome keeps more of each dollar of sales as profit, with a net margin of −859% compared with −893% at Lucid Diagnostics.
Lucid Diagnostics scores higher on the StockData Score (7 against 5 for Cerenome), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CNSY | LUCD |
|---|---|---|
| Size and price | ||
| Market cap | $7.2M | $91.3M |
| Share price | $0.950 | $0.449 |
| Change, 1 year | −93.2% | −59.5% |
| Change, 5 years | −97.5% | −95.2% |
| Beta (5Y) | 0.59 | 1.04 |
| Employees | 28 | 82 |
| StockData Score | ||
| Total score | 5 | 7 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 3 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.0× (better) | 16.8× |
| P/B | – | 15.4× |
| FCF yield | −398% | −56.8% (better) |
| Fair value | – | $0.253 |
| Margin of safety | – | −77.8% |
| Growth | ||
| Revenue growth (TTM) | −32.9% | 23.6% (better) |
| Profitability | ||
| Gross margin | – | −16.5% |
| Operating margin | −833% (better) | −942% |
| Net margin | −859% (better) | −893% |
| FCF margin | −813% (better) | −953% |
| Return on equity | −1468% | −306% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −815.9× (better) | −3011.9× |
| Current ratio | 0.61 | 1.20 (better) |
| Altman Z-score | −69.85 | −19.24 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 8.3% | 30.2% |
| Held by insiders | 4.2% | 24.8% |
| Insider net buying, 12 months | $0 | $245K (better) |
| Short interest, % of float | 11.6% | 9.8% |
Go deeper
- CNSY stock overview
- CNSY income statement
- CNSY valuation and score
- LUCD stock overview
- LUCD income statement
- LUCD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.